ALLMedicine™ Congenital Hyperinsulinism Center

Nov 22nd, 2022 - To evaluate and present the data regarding clinical, laboratory, radiological and the results of molecular genetic analysis of patients with hyperinsulinemic hypoglycemia in our clinics. A total of 9 patients with CHI followed at Istanbul Medipol ...

Nov 6th, 2022 - Disrupted β-cell-specific gene silencing causes congenital hyperinsulinism.|2022||

Nov 6th, 2022 - Gene expression is tightly regulated, with many genes exhibiting cell-specific silencing when their protein product would disrupt normal cellular function1. This silencing is largely controlled by non-coding elements, and their disruption might ca...

Oct 15th, 2022 - Congenital hyperinsulinism (HI) is characterised by inappropriate insulin secretion despite low blood glucose. Persistent HI is often monogenic, with the majority of cases diagnosed in infancy. Less is known about the contribution of monogenic for...

Oct 13th, 2022 - For children with congenital hyperinsulinism (CHI), low blood sugar is caused by cells in the pancreas that release too much insulin. Some children with CHI have these cells throughout their pancreas (called diffuse disease); others have them loca...

Oct 13th, 2022 - For children with congenital hyperinsulinism (CHI), low blood sugar is caused by cells in the pancreas that release too much insulin. Some children with CHI have these cells throughout their pancreas (called diffuse disease); others have them loca...

Oct 3rd, 2022 - This is an open-label, multinational, multicenter, long-term safety and efficacy extension trial in patients with Congenital Hyperinsulinism (CHI) who completed either ZP4207-17103 or ZP4207-17109 (defined as lead-in trials). The primary objective...

Oct 3rd, 2022 - The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hyp...

Sep 27th, 2022 - This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC). HM15136 will be ad...

Sep 8th, 2022 - There is a significant unmet medical need to develop new therapies aimed at preventing chronic recurrent hypoglycemia in congenital HI, the most common cause of persistent hypoglycemia in children. RZ358 is a human mAb that allosterically attenuat...

May 24th, 2022 - Dasiglucagon reduced the need for IV glucose by 55% versus placebo in a pediatric population with congenital hyperinsulinism, according to a second phase III clinical trial by Zealand Pharma. The American Diabetes Association praised Maryland Gov....

Apr 21st, 2022 - An investigational glucagon-like peptide-1 (GLP-1) antagonist, exendin-(9-39), prevents fasting and protein-induced hypoglycemia among children with congenital hyperinsulinism, new data suggest.   Results from the open-label crossover phase 2 tria...

Mar 22nd, 2022 - Children who experienced low blood sugar as newborns did not have different academic performance results 10 years later compared with those who did not have hypoglycemia, new results from the CHYLD study suggest, conflicting with previous findings...

Nov 13th, 2019 - EPI is characterized by a deficiency of the above mentioned exocrine pancreatic enzymes, which results in an inability to digest food properly (maldigestion). Because pancreatic lipase accounts for up to 90% of fat digestion, maldigestion of fat i...

Apr 12th, 2019 - The International Pediatric Association biennial meeting has long focused on the terrifying list of threats to child health: poverty, malnutrition, vaccine-preventable disease, toxic stress. But this year's meeting, held in Panama City, Panama, Ma...